Sitagliptin / Metformin hydrochloride Accord

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Unduh Selebaran informasi (PIL)
01-09-2022
Unduh Karakteristik produk (SPC)
01-09-2022

Bahan aktif:

metformin hydrochloride, sitagliptin hydrochloride monohydrate

Tersedia dari:

Accord Healthcare S.L.U.

Kode ATC:

A10BD07

INN (Nama Internasional):

sitagliptin, metformin hydrochloride

Kelompok Terapi:

Drugs used in diabetes

Area terapi:

Diabetes Mellitus, Type 2

Indikasi Terapi:

For adult patients with type 2 diabetes mellitus:It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Ringkasan produk:

Revision: 1

Status otorisasi:

Authorised

Tanggal Otorisasi:

2022-07-22

Selebaran informasi

                                35
B. PACKAGE LEAFLET
36
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SITAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/850 MG
FILM-COATED TABLETS
SITAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/1,000 MG
FILM-COATED TABLETS
sitagliptin/metformin hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist, or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sitagliptin/Metformin hydrochloride Accord is and what it is used
for
2.
What you need to know before you take Sitagliptin/Metformin
hydrochloride Accord
3.
How to take Sitagliptin/Metformin hydrochloride Accord
4.
Possible side effects
5.
How to store Sitagliptin/Metformin hydrochloride Accord
6.
Contents of the pack and other information
1.
WHAT SITAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD IS AND WHAT IT IS USED
FOR
This medicine contains two different medicines called sitagliptin and
metformin.
•
sitagliptin belongs to a class of medicines called DPP-4 inhibitors
(dipeptidyl peptidase-4
inhibitors)
•
metformin belongs to a class of medicines called biguanides.
They work together to control blood sugar levels in adult patients
with a form of diabetes called
‘type 2 diabetes mellitus’. This medicine helps to increase the
levels of insulin produced after a meal
and lowers the amount of sugar made by your body.
Along with diet and exercise, this medicine helps lower your blood
sugar. This medicine can be used
alone or with certain other medicines for diabetes (insulin,
sulphonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a condition in which your body
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sitagliptin/Metformin hydrochloride Accord 50 mg/850 mg film-coated
tablets
Sitagliptin/Metformin hydrochloride Accord 50 mg/1,000 mg film-coated
tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Sitagliptin/Metformin hydrochloride Accord 50 mg/850 mg film-coated
tablets
Each tablet contains sitagliptin hydrochloride monohydrate equivalent
to 50 mg of sitagliptin and
850 mg of metformin hydrochloride.
Sitagliptin/Metformin hydrochloride Accord 50 mg/1,000 mg film-coated
tablets
Each tablet contains sitagliptin hydrochloride monohydrate equivalent
to 50 mg of sitagliptin and
1,000 mg of metformin hydrochloride.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Sitagliptin/Metformin hydrochloride Accord 50 mg/850 mg film-coated
tablets
Pink colored, capsule shaped, film coated tablet debossed with 'SM2'
on one side and plain on other
side. Dimension: 20x10 mm.
Sitagliptin/Metformin hydrochloride Accord 50 mg/1,000 mg film-coated
tablets
Red colored, capsule shaped, film coated tablet debossed with 'SM3' on
one side and plain on other
side. Dimension: Length: 21x10 mm
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For adult patients with type 2 diabetes mellitus:
It is indicated as an adjunct to diet and exercise to improve
glycaemic control in patients inadequately
controlled on their maximal tolerated dose of metformin alone or those
already being treated with the
combination of sitagliptin and metformin.
It is indicated in combination with a sulphonylurea (i.e., triple
combination therapy) as an adjunct to
diet and exercise in patients inadequately controlled on their maximal
tolerated dose of metformin and
a sulphonylurea.
It is indicated as triple combination therapy with a peroxisome
proliferator-activated receptor gamma
(PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and
exercise in patients inadequately
controlled on their maximal tolerated dose of metf
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 01-09-2022
Karakteristik produk Karakteristik produk Bulgar 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 03-08-2022
Selebaran informasi Selebaran informasi Spanyol 01-09-2022
Karakteristik produk Karakteristik produk Spanyol 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 03-08-2022
Selebaran informasi Selebaran informasi Cheska 01-09-2022
Karakteristik produk Karakteristik produk Cheska 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 03-08-2022
Selebaran informasi Selebaran informasi Dansk 01-09-2022
Karakteristik produk Karakteristik produk Dansk 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 03-08-2022
Selebaran informasi Selebaran informasi Jerman 01-09-2022
Karakteristik produk Karakteristik produk Jerman 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 03-08-2022
Selebaran informasi Selebaran informasi Esti 01-09-2022
Karakteristik produk Karakteristik produk Esti 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 03-08-2022
Selebaran informasi Selebaran informasi Yunani 01-09-2022
Karakteristik produk Karakteristik produk Yunani 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 03-08-2022
Selebaran informasi Selebaran informasi Prancis 01-09-2022
Karakteristik produk Karakteristik produk Prancis 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 03-08-2022
Selebaran informasi Selebaran informasi Italia 01-09-2022
Karakteristik produk Karakteristik produk Italia 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 03-08-2022
Selebaran informasi Selebaran informasi Latvi 01-09-2022
Karakteristik produk Karakteristik produk Latvi 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 03-08-2022
Selebaran informasi Selebaran informasi Lituavi 01-09-2022
Karakteristik produk Karakteristik produk Lituavi 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 03-08-2022
Selebaran informasi Selebaran informasi Hungaria 01-09-2022
Karakteristik produk Karakteristik produk Hungaria 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 03-08-2022
Selebaran informasi Selebaran informasi Malta 01-09-2022
Karakteristik produk Karakteristik produk Malta 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 03-08-2022
Selebaran informasi Selebaran informasi Belanda 01-09-2022
Karakteristik produk Karakteristik produk Belanda 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 03-08-2022
Selebaran informasi Selebaran informasi Polski 01-09-2022
Karakteristik produk Karakteristik produk Polski 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 03-08-2022
Selebaran informasi Selebaran informasi Portugis 01-09-2022
Karakteristik produk Karakteristik produk Portugis 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 03-08-2022
Selebaran informasi Selebaran informasi Rumania 01-09-2022
Karakteristik produk Karakteristik produk Rumania 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 03-08-2022
Selebaran informasi Selebaran informasi Slovak 01-09-2022
Karakteristik produk Karakteristik produk Slovak 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 03-08-2022
Selebaran informasi Selebaran informasi Sloven 01-09-2022
Karakteristik produk Karakteristik produk Sloven 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 03-08-2022
Selebaran informasi Selebaran informasi Suomi 01-09-2022
Karakteristik produk Karakteristik produk Suomi 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 03-08-2022
Selebaran informasi Selebaran informasi Swedia 01-09-2022
Karakteristik produk Karakteristik produk Swedia 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 03-08-2022
Selebaran informasi Selebaran informasi Norwegia 01-09-2022
Karakteristik produk Karakteristik produk Norwegia 01-09-2022
Selebaran informasi Selebaran informasi Islandia 01-09-2022
Karakteristik produk Karakteristik produk Islandia 01-09-2022
Selebaran informasi Selebaran informasi Kroasia 01-09-2022
Karakteristik produk Karakteristik produk Kroasia 01-09-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 03-08-2022